Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.

19 Jan 2024

Abstract excerpt

There remains a striking overall mortality burden of COVID-19 worldwide. Given the waning effectiveness of current SARS-CoV-2 antivirals due to the rapid emergence of new variants of concern (VOC), we employed a direct-acting molecular therapy approach using gene silencing RNA interference (RNAi) technology. In this study, we developed and screened several ultra-conserved small-interfering RNAs (siRNAs) before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38246206
DOI: 10.1016/j.antiviral.2024.105815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.PMID 38246206Read ↗

Prospects for RNAi Therapy of COVID-19Semantic proximity Read ↗

Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infectionSemantic proximity Read ↗

Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2Semantic proximity Read ↗

Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIVSemantic proximity Read ↗

An intranasal ASO therapeutic targeting SARS-CoV-2Semantic proximity Read ↗

Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxisSemantic proximity Read ↗

In Silico and In Vitro development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2Semantic proximity Read ↗

Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based deliverySemantic proximity Read ↗

Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape MechanismsSemantic proximity Read ↗

In Silico and In Vitro Development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2Semantic proximity Read ↗

Inhibition of SARS-CoV-2 Replication by Self-Assembled siRNA Nanoparticles Targeting Multiple Highly Conserved Viral SequencesSemantic proximity Read ↗

Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSVSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.